The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oligonucleotide Therapy Market Research Report 2024
Synopsis
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global Oligonucleotide Therapy market was valued at US$ 3678.1 million in 2023 and is anticipated to reach US$ 4746.7 million by 2030, witnessing a CAGR of 3.6% during the forecast period 2024-2030.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapy.
Report Scope
The Oligonucleotide Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals Inc.
Biogen
Dynavax Technologies Corp.
Merck and Co.
Miragen Therapeuutics Inc.
Sarepta Therapeutics Inc.
GlaxoSmithKline
Pfizer
Gilead Sciences
Segment by Type
Antisense Oligonucleotide
Aptamer
Others
Segment by Application
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global Oligonucleotide Therapy market was valued at US$ 3678.1 million in 2023 and is anticipated to reach US$ 4746.7 million by 2030, witnessing a CAGR of 3.6% during the forecast period 2024-2030.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapy.
Report Scope
The Oligonucleotide Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Alnylam Pharmaceuticals Inc.
Biogen
Dynavax Technologies Corp.
Merck and Co.
Miragen Therapeuutics Inc.
Sarepta Therapeutics Inc.
GlaxoSmithKline
Pfizer
Gilead Sciences
Segment by Type
Antisense Oligonucleotide
Aptamer
Others
Segment by Application
Infectious Diseases
Oncology
Neurodegenerative Disorders
Cardiovascular Diseases
Kidney Diseases
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oligonucleotide Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oligonucleotide Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Others
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Infectious Diseases
1.3.3 Oncology
1.3.4 Neurodegenerative Disorders
1.3.5 Cardiovascular Diseases
1.3.6 Kidney Diseases
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oligonucleotide Therapy Market Perspective (2019-2030)
2.2 Oligonucleotide Therapy Growth Trends by Region
2.2.1 Global Oligonucleotide Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Oligonucleotide Therapy Historic Market Size by Region (2019-2024)
2.2.3 Oligonucleotide Therapy Forecasted Market Size by Region (2025-2030)
2.3 Oligonucleotide Therapy Market Dynamics
2.3.1 Oligonucleotide Therapy Industry Trends
2.3.2 Oligonucleotide Therapy Market Drivers
2.3.3 Oligonucleotide Therapy Market Challenges
2.3.4 Oligonucleotide Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Oligonucleotide Therapy Players by Revenue
3.1.1 Global Top Oligonucleotide Therapy Players by Revenue (2019-2024)
3.1.2 Global Oligonucleotide Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Oligonucleotide Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Oligonucleotide Therapy Revenue
3.4 Global Oligonucleotide Therapy Market Concentration Ratio
3.4.1 Global Oligonucleotide Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oligonucleotide Therapy Revenue in 2023
3.5 Oligonucleotide Therapy Key Players Head office and Area Served
3.6 Key Players Oligonucleotide Therapy Product Solution and Service
3.7 Date of Enter into Oligonucleotide Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Oligonucleotide Therapy Breakdown Data by Type
4.1 Global Oligonucleotide Therapy Historic Market Size by Type (2019-2024)
4.2 Global Oligonucleotide Therapy Forecasted Market Size by Type (2025-2030)
5 Oligonucleotide Therapy Breakdown Data by Application
5.1 Global Oligonucleotide Therapy Historic Market Size by Application (2019-2024)
5.2 Global Oligonucleotide Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Oligonucleotide Therapy Market Size (2019-2030)
6.2 North America Oligonucleotide Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Oligonucleotide Therapy Market Size by Country (2019-2024)
6.4 North America Oligonucleotide Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Oligonucleotide Therapy Market Size (2019-2030)
7.2 Europe Oligonucleotide Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Oligonucleotide Therapy Market Size by Country (2019-2024)
7.4 Europe Oligonucleotide Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Therapy Market Size (2019-2030)
8.2 Asia-Pacific Oligonucleotide Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Oligonucleotide Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Oligonucleotide Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Oligonucleotide Therapy Market Size (2019-2030)
9.2 Latin America Oligonucleotide Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Oligonucleotide Therapy Market Size by Country (2019-2024)
9.4 Latin America Oligonucleotide Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Oligonucleotide Therapy Market Size (2019-2030)
10.2 Middle East & Africa Oligonucleotide Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Oligonucleotide Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Oligonucleotide Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alnylam Pharmaceuticals Inc.
11.1.1 Alnylam Pharmaceuticals Inc. Company Detail
11.1.2 Alnylam Pharmaceuticals Inc. Business Overview
11.1.3 Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Introduction
11.1.4 Alnylam Pharmaceuticals Inc. Revenue in Oligonucleotide Therapy Business (2019-2024)
11.1.5 Alnylam Pharmaceuticals Inc. Recent Development
11.2 Biogen
11.2.1 Biogen Company Detail
11.2.2 Biogen Business Overview
11.2.3 Biogen Oligonucleotide Therapy Introduction
11.2.4 Biogen Revenue in Oligonucleotide Therapy Business (2019-2024)
11.2.5 Biogen Recent Development
11.3 Dynavax Technologies Corp.
11.3.1 Dynavax Technologies Corp. Company Detail
11.3.2 Dynavax Technologies Corp. Business Overview
11.3.3 Dynavax Technologies Corp. Oligonucleotide Therapy Introduction
11.3.4 Dynavax Technologies Corp. Revenue in Oligonucleotide Therapy Business (2019-2024)
11.3.5 Dynavax Technologies Corp. Recent Development
11.4 Merck and Co.
11.4.1 Merck and Co. Company Detail
11.4.2 Merck and Co. Business Overview
11.4.3 Merck and Co. Oligonucleotide Therapy Introduction
11.4.4 Merck and Co. Revenue in Oligonucleotide Therapy Business (2019-2024)
11.4.5 Merck and Co. Recent Development
11.5 Miragen Therapeuutics Inc.
11.5.1 Miragen Therapeuutics Inc. Company Detail
11.5.2 Miragen Therapeuutics Inc. Business Overview
11.5.3 Miragen Therapeuutics Inc. Oligonucleotide Therapy Introduction
11.5.4 Miragen Therapeuutics Inc. Revenue in Oligonucleotide Therapy Business (2019-2024)
11.5.5 Miragen Therapeuutics Inc. Recent Development
11.6 Sarepta Therapeutics Inc.
11.6.1 Sarepta Therapeutics Inc. Company Detail
11.6.2 Sarepta Therapeutics Inc. Business Overview
11.6.3 Sarepta Therapeutics Inc. Oligonucleotide Therapy Introduction
11.6.4 Sarepta Therapeutics Inc. Revenue in Oligonucleotide Therapy Business (2019-2024)
11.6.5 Sarepta Therapeutics Inc. Recent Development
11.7 GlaxoSmithKline
11.7.1 GlaxoSmithKline Company Detail
11.7.2 GlaxoSmithKline Business Overview
11.7.3 GlaxoSmithKline Oligonucleotide Therapy Introduction
11.7.4 GlaxoSmithKline Revenue in Oligonucleotide Therapy Business (2019-2024)
11.7.5 GlaxoSmithKline Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Oligonucleotide Therapy Introduction
11.8.4 Pfizer Revenue in Oligonucleotide Therapy Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Gilead Sciences
11.9.1 Gilead Sciences Company Detail
11.9.2 Gilead Sciences Business Overview
11.9.3 Gilead Sciences Oligonucleotide Therapy Introduction
11.9.4 Gilead Sciences Revenue in Oligonucleotide Therapy Business (2019-2024)
11.9.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Oligonucleotide Therapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Antisense Oligonucleotide
Table 3. Key Players of Aptamer
Table 4. Key Players of Others
Table 5. Global Oligonucleotide Therapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Oligonucleotide Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Oligonucleotide Therapy Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Oligonucleotide Therapy Market Share by Region (2019-2024)
Table 9. Global Oligonucleotide Therapy Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Oligonucleotide Therapy Market Share by Region (2025-2030)
Table 11. Oligonucleotide Therapy Market Trends
Table 12. Oligonucleotide Therapy Market Drivers
Table 13. Oligonucleotide Therapy Market Challenges
Table 14. Oligonucleotide Therapy Market Restraints
Table 15. Global Oligonucleotide Therapy Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Oligonucleotide Therapy Market Share by Players (2019-2024)
Table 17. Global Top Oligonucleotide Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy as of 2023)
Table 18. Ranking of Global Top Oligonucleotide Therapy Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Oligonucleotide Therapy Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Oligonucleotide Therapy Product Solution and Service
Table 22. Date of Enter into Oligonucleotide Therapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Oligonucleotide Therapy Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Oligonucleotide Therapy Revenue Market Share by Type (2019-2024)
Table 26. Global Oligonucleotide Therapy Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Oligonucleotide Therapy Revenue Market Share by Type (2025-2030)
Table 28. Global Oligonucleotide Therapy Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Oligonucleotide Therapy Revenue Market Share by Application (2019-2024)
Table 30. Global Oligonucleotide Therapy Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Oligonucleotide Therapy Revenue Market Share by Application (2025-2030)
Table 32. North America Oligonucleotide Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Oligonucleotide Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Oligonucleotide Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Oligonucleotide Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Oligonucleotide Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Oligonucleotide Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Oligonucleotide Therapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Oligonucleotide Therapy Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Oligonucleotide Therapy Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Oligonucleotide Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Oligonucleotide Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Oligonucleotide Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Oligonucleotide Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Oligonucleotide Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Oligonucleotide Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 47. Alnylam Pharmaceuticals Inc. Company Detail
Table 48. Alnylam Pharmaceuticals Inc. Business Overview
Table 49. Alnylam Pharmaceuticals Inc. Oligonucleotide Therapy Product
Table 50. Alnylam Pharmaceuticals Inc. Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 51. Alnylam Pharmaceuticals Inc. Recent Development
Table 52. Biogen Company Detail
Table 53. Biogen Business Overview
Table 54. Biogen Oligonucleotide Therapy Product
Table 55. Biogen Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 56. Biogen Recent Development
Table 57. Dynavax Technologies Corp. Company Detail
Table 58. Dynavax Technologies Corp. Business Overview
Table 59. Dynavax Technologies Corp. Oligonucleotide Therapy Product
Table 60. Dynavax Technologies Corp. Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 61. Dynavax Technologies Corp. Recent Development
Table 62. Merck and Co. Company Detail
Table 63. Merck and Co. Business Overview
Table 64. Merck and Co. Oligonucleotide Therapy Product
Table 65. Merck and Co. Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 66. Merck and Co. Recent Development
Table 67. Miragen Therapeuutics Inc. Company Detail
Table 68. Miragen Therapeuutics Inc. Business Overview
Table 69. Miragen Therapeuutics Inc. Oligonucleotide Therapy Product
Table 70. Miragen Therapeuutics Inc. Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 71. Miragen Therapeuutics Inc. Recent Development
Table 72. Sarepta Therapeutics Inc. Company Detail
Table 73. Sarepta Therapeutics Inc. Business Overview
Table 74. Sarepta Therapeutics Inc. Oligonucleotide Therapy Product
Table 75. Sarepta Therapeutics Inc. Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 76. Sarepta Therapeutics Inc. Recent Development
Table 77. GlaxoSmithKline Company Detail
Table 78. GlaxoSmithKline Business Overview
Table 79. GlaxoSmithKline Oligonucleotide Therapy Product
Table 80. GlaxoSmithKline Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 81. GlaxoSmithKline Recent Development
Table 82. Pfizer Company Detail
Table 83. Pfizer Business Overview
Table 84. Pfizer Oligonucleotide Therapy Product
Table 85. Pfizer Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 86. Pfizer Recent Development
Table 87. Gilead Sciences Company Detail
Table 88. Gilead Sciences Business Overview
Table 89. Gilead Sciences Oligonucleotide Therapy Product
Table 90. Gilead Sciences Revenue in Oligonucleotide Therapy Business (2019-2024) & (US$ Million)
Table 91. Gilead Sciences Recent Development
Table 92. Research Programs/Design for This Report
Table 93. Key Data Information from Secondary Sources
Table 94. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oligonucleotide Therapy Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Oligonucleotide Therapy Market Share by Type: 2023 VS 2030
Figure 3. Antisense Oligonucleotide Features
Figure 4. Aptamer Features
Figure 5. Others Features
Figure 6. Global Oligonucleotide Therapy Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Oligonucleotide Therapy Market Share by Application: 2023 VS 2030
Figure 8. Infectious Diseases Case Studies
Figure 9. Oncology Case Studies
Figure 10. Neurodegenerative Disorders Case Studies
Figure 11. Cardiovascular Diseases Case Studies
Figure 12. Kidney Diseases Case Studies
Figure 13. Others Case Studies
Figure 14. Oligonucleotide Therapy Report Years Considered
Figure 15. Global Oligonucleotide Therapy Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Oligonucleotide Therapy Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Oligonucleotide Therapy Market Share by Region: 2023 VS 2030
Figure 18. Global Oligonucleotide Therapy Market Share by Players in 2023
Figure 19. Global Top Oligonucleotide Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide Therapy as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Oligonucleotide Therapy Revenue in 2023
Figure 21. North America Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Oligonucleotide Therapy Market Share by Country (2019-2030)
Figure 23. United States Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Oligonucleotide Therapy Market Share by Country (2019-2030)
Figure 27. Germany Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Oligonucleotide Therapy Market Share by Region (2019-2030)
Figure 35. China Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Oligonucleotide Therapy Market Share by Country (2019-2030)
Figure 43. Mexico Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Oligonucleotide Therapy Market Share by Country (2019-2030)
Figure 47. Turkey Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Oligonucleotide Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 50. Biogen Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 51. Dynavax Technologies Corp. Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 52. Merck and Co. Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 53. Miragen Therapeuutics Inc. Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 54. Sarepta Therapeutics Inc. Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 55. GlaxoSmithKline Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 56. Pfizer Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 57. Gilead Sciences Revenue Growth Rate in Oligonucleotide Therapy Business (2019-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
